Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Pharmacokinetics of HS-20136-2 in Healthy Participants
NCT07483437Phase 1Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- May 2026
- Primary completion
- Dec 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing HS-20136-2 injection with Placebo (2 arms). Primary endpoints: Incidence of adverse events at Day 57, Incidence of serious adverse events at Day 57 and 2 more. Planned start May 2026; status: not yet recruiting.
02
Drugs
HS-20136-2
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07483437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07483437.